HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Get Rating) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $18.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Capricor Therapeutics’ Q1 2023 earnings at ($0.32) EPS, Q2 2023 earnings at ($0.34) EPS, Q3 2023 earnings at ($0.33) EPS and Q4 2023 earnings at ($0.42) EPS.
Separately, StockNews.com started coverage on shares of Capricor Therapeutics in a research note on Thursday. They set a sell rating for the company.
Capricor Therapeutics Stock Down 4.7 %
CAPR stock opened at $4.34 on Thursday. Capricor Therapeutics has a twelve month low of $2.81 and a twelve month high of $6.58. The company has a market cap of $109.54 million, a PE ratio of -3.68 and a beta of 4.07. The business’s 50-day simple moving average is $4.35 and its 200 day simple moving average is $4.76.
Institutional Inflows and Outflows
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.